Sacituzumab govitecan

Phase 2Recruiting

0 views this week 0 watching⚡ Active

Interest: 42/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Differentiated Thyroid Cancer

Conditions

Differentiated Thyroid Cancer, Anaplastic Thyroid Cancer

Trial Timeline

Sep 13, 2024 → Dec 1, 2027

NCT ID

NCT06235216

About Sacituzumab govitecan

Sacituzumab govitecan is a phase 2 stage product being developed by Gilead Sciences for Differentiated Thyroid Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06235216. Target conditions include Differentiated Thyroid Cancer, Anaplastic Thyroid Cancer.

What happened to similar drugs?

1 of 8 similar drugs in Differentiated Thyroid Cancer were approved

Approved (1) Terminated (1) Active (6)

✅sunitinibPfizerApproved

🔄Abemaciclib + PlaceboEli LillyPhase 3

🔄Lenvatinib + PlaceboEisaiPhase 3

❌Selumetinib + Placebo + Radioactive Iodine TherapyAstraZenecaPhase 3

🔄Dabrafenib + Trametinib + Trametinib Placebo + Dabrafenib placeboNovartisPhase 3

🔄Vandetanib (SAR390530) + PlaceboSanofiPhase 3

🔄Thyrogen (thyrotropin alfa for injection)SanofiPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (16)

NCT ID	Phase	Status	Start	Completion	Indication
NCT06923826	Phase 2	Recruiting	Apr 15, 2025	Apr 1, 2030	Salivary Gland Cancer
NCT06665178	Phase 2	Recruiting	Mar 31, 2025	Dec 1, 2028	Breast Cancer
NCT06235216	Phase 2	Recruiting	Sep 13, 2024	Dec 1, 2027	Differentiated Thyroid Cancer
NCT06329869	Phase 2	Recruiting	Aug 1, 2024	Nov 1, 2027	Esophageal Squamous Cell Carcinoma
NCT06263543	Phase 2	Recruiting	Jun 17, 2024	Dec 1, 2026	Breast Cancer
NCT06123468	Phase 1/2	Completed	Apr 17, 2024	Jan 7, 2026	Esophagogastric Adenocarcinoma
NCT05833867	Phase 1	Recruiting	Apr 1, 2024	Oct 1, 2027	Localized Muscle Invasive Bladder Urothelial Carcinoma
NCT06028932	Phase 2	Active	Jan 8, 2024	Nov 1, 2027	Ovarian Carcinoma
NCT05552001	Phase 3	Recruiting	Oct 5, 2023	May 6, 2028	Triple Negative Breast Cancer
NCT05884320	Phase 2	Recruiting	Jul 27, 2023	Jul 31, 2028	Gland
NCT05581589	Phase 2	Recruiting	Jun 15, 2023	Apr 30, 2027	Muscle Invasive Bladder Carcinoma
NCT05838521	Phase 2	Recruiting	Jun 2, 2023	Jun 1, 2028	Cervical Cancer
NCT04647916	Phase 2	Active	Jun 8, 2021	Dec 1, 2028	Anatomic Stage IV Breast Cancer AJCC v8
NCT04251416	Phase 2	Active	Mar 17, 2020	Feb 1, 2027	Endometrial Carcinoma
NCT03995706	Phase 1	Completed	Jul 17, 2019	Mar 20, 2024	Glioblastoma
NCT03725761	Phase 2	Active	Oct 24, 2018	Sep 1, 2027	Prostate Cancer

Competing Products

20 competing products in Differentiated Thyroid Cancer

See all competitors

Product	Company	Stage	Hype Score
CAB-AXL-ADC + PD-1 inhibitor	BioAtla	Phase 1/2	22
Abemaciclib + Placebo	Eli Lilly	Phase 3	44
Lenvatinib + Placebo	Eisai	Phase 3	40
Lenvatinib	Eisai	Pre-clinical	26
Lenvatinib	Eisai	Phase 2	27
LENVATINIB	Eisai	Phase 2	39
Selpercatinib Monotherapy	Eli Lilly	Phase 2	42
Selumetinib + Placebo + Radioactive Iodine Therapy	AstraZeneca	Phase 3	32
Pembrolizumab + Cisplatin + Docetaxel + Carboplatin	Merck	Phase 2	42
Pembrolizumab	Merck	Phase 2	42
sunitinib + everolimus + chemotherapies recommended in france	Novartis	Pre-clinical	26
Everolimus + Sorafenib	Novartis	Phase 2	31
Dabrafenib + Trametinib + Trametinib Placebo + Dabrafenib placebo	Novartis	Phase 3	44
PDR001	Novartis	Phase 2	35
Everolimus (Afinitor®)	Novartis	Phase 2	35
sunitinib	Pfizer	Approved	43
Vandetanib (SAR390530) + Placebo	Sanofi	Phase 3	40
Thyrogen (thyrotropin alfa for injection)	Sanofi	Phase 3	40
Cabazitaxel	Sanofi	Phase 2	35
Larotrectinib monotherapy	Bayer	Phase 2	39